I begge forsøg var i alt 67% patientvira resistente, og 22% var muligvis resistente over for på forhånd udvalgte komparator- proteasehæmmere.
In both studies, a total of 67% patient viruses were resistant and 22% were possibly resistant to the pre-selected comparator PIs.